SEATTLE, Nov. 30,
2023 /PRNewswire/ -- Presage Biosciences, a
pioneering translational oncology company whose mission is to use
CIVO and spatial molecular profiling to understand the complexity
of drug response in the tumor microenvironment (TME), has entered
into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global
biopharmaceutical company. According to the agreement, Presage's
platform will be used by AstraZeneca in translational analysis to
evaluate several investigational bispecific antibody combinations
in samples taken from head and neck cancer patients. The work will
contribute to advancing AstraZeneca's growing portfolio of
immuno-oncology agents looking to harness the immune system against
cancer.
![Presage Biosciences, Inc. Presage Biosciences, Inc.](https://mma.prnewswire.com/media/2288909/presagebio_lowres_med_Logo.jpg)
Rich Klinghoffer, PhD, Chief
Executive Officer of Presage, said: "Prior studies have
demonstrated that the CIVO platform provides accurate guidance
about the therapeutic potential of novel agents in the only context
that matters: Fully intact patient tumors. We are very pleased to
be working with an innovator like AstraZeneca and supporting their
quest to discover, develop, and deliver transformative medicines to
patients."
Earlier this month, Presage presented results from a completed
Phase 0 study evaluating Merck's anti-PD-1 therapy KEYTRUDA®
(pembrolizumab) alone and in combination with other immune-oncology
agents at the Society for Immunotherapy of Cancer (SITC) 2023
Annual Meeting. The study enrolled patients across six US-based
cancer centers in both soft tissue sarcoma and head and neck
cancer. Study data highlight the importance of evaluating novel
therapies in patient tumors and revealed a contradiction between
results from in-vivo animal studies versus results in the intact
TME.
"For too long, we have put our trust in laboratory models of
cancer that do not capture the complexity of the intact TME," said
Klinghoffer. "The CIVO technology was developed to address
this fundamental issue in cancer drug development and the results
from this study demonstrate the true power of our platform - the
ability to know, early in development, how a drug impacts patient
tumors."
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About CIVO
Clinical In Vivo Oncology (CIVO) is Presage's patented platform
that enables multiplexed intratumoral microdosing and generation of
deep spatial biology insights. The platform enables evaluation of
up to eight distinct and trackable drugs and drug combinations
simultaneously. Presage's CIVO technology and analysis capabilities
are unparalleled at providing insight into drug-exposed areas of
the intact tumor microenvironment. Presage is pairing the use of
CIVO with molecular profiling technologies in Phase 0 trials in
order to inform and de-risk drug development.
About Presage
Presage Biosciences is a translational oncology company
dedicated to understanding the complexity of drug response in the
tumor microenvironment. Presage partners with oncology-focused
pharmaceutical companies through strategic alliances along with
other innovators who are at the forefront of spatial biology and
oncology drug development. Presage is privately held and based
in Seattle. For more information,
visit www.presagebio.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/presage-biosciences-announces-new-pharma-partnership-to-evaluate-novel-immuno-oncology-drug-combinations-with-civo-technology-302001709.html
SOURCE Presage Biosciences Inc